The goal of this activity is for learners to be better able to describe CAR-T cell kinetics and their association with efficacy and toxicity in a retrospective analysis of patients with RRMM treated with idecabtagene vicleucel (ide-cel; n=36) or ciltacabtagene autoleucel (cilta-cel; n=54), using a uniform flow cytometry-based platform; and describe clinically accessible biomarkers of CAR-T cell expansion using absolute lymphocyte count (ALC) as a surrogate biomarker in a larger multicenter cohort (ide-cel, n=276; cilta-cel, n=256).
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
This is a journal-based activity. Credit is earned after completing the required reading and assessment; the amount shown is the provider-reported available credit.
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 283 - 299 Market St.
Pricing
100% of listed courses are free
300 of a sample of 300 are free · 1,253 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Breast Imaging
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Clinical Informatics
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Facial Plastic & Reconstructive Surgery
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Nuclear Medicine
- Obstetric Anesthesia
- Obstetrics & Gynecology
- Ophthalmology
- Otology & Neurotology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Gastroenterology
- Pediatric Neurology
- Plastic & Reconstructive Surgery
- Preventive Medicine
- Primary Care Sports Medicine
- Pulmonary Disease
- Rheumatology
- Rhinology
- Sleep Medicine
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Sports & Exercise Medicine
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Journal-based
- Credit · Up to 1 credit
- MOC · Up to 1 point
-
Available fromOct 15, 2026
-
Last day to claim creditOct 16, 2027 1 year left
-
Catalyst Medical Education, LLC +1 Navigating the Bridge to CAR-T: Conversations and Cases on Individualized Bridging Strategies
-
Global Learning Collaborative The Frontline Imperative: Integrating Anti-CD38 Based Regimens Into Multiple Myeloma Care in Community Practice
-
Clinical Care Options, LLC (dba Decera Clinical Education) Optimizing Integration of Bispecific Antibody Therapy to Improve Clinical Outcomes in Patients With Multiple Myeloma
-
American Society of Hematology +1 Isatuximab in Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
-
Medscape, LLC The (R)Evolution of CAR T-Cell Therapy in Neurological Autoimmune Diseases: SPS and MG
-
Medscape, LLC Focusing on Ocular Toxicities in Multiple Myeloma Management
